3 Biotech Stocks to Sell in August Before They Crash & Burn 3 Biotech Stocks to Sell in August Before They Crash & Burn | Markets

For investors, one of the most attractive aspects of biotech stocks is their ability to increase in value in a short period of time quickly. After all, it only takes one major breakthrough in clinical trials or a Food and Drug Administration approval to rush a stock into the headlines rapidly. Yet, as quickly as these securities go up, so too can they come down, resulting in biotech stocks to sell.

In these cases, investors who act quickly or see through the hype can avoid portfolio losses while maximizing profits from a bull run. An example of this would be savvy investors who foresaw the overvaluations of Pfizer (NYSE:PFE) and Moderna (NYSE:MRNA) at the height of the COVID-19 pandemic. Getting out of these positions back then would have been incredibly lucrative, as it’s unlikely they will return to those levels any time soon. As such, here are three biotech stocks to sell before they begin to trend down as a result of slowing sales or disappointing reports.

Lyell Immunopharma (LYEL)

One of many biotech stocks in the early stages of treatment development, Lyell Immunopharma (NASDAQ:LYEL) has struggled to attract investor excitement with its proprietary immune system treatments for fighting cancer. The company’s…